Experience

Windward Bio Closes $200 Million Series A

January 10, 2025

Cooley advised Windward Bio, a clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases, on its $200 million Series A financing round. Partners Brandon Fenn and Ryan Sansom led the Cooley team advising Windward Bio.

Related contacts

Brandon W. Fenn
Partner, New York
Ryan Sansom
Partner, Boston
Alex Abelson
Associate, New York

Related Practices & Industries

Keros Therapeutics Announces Ex-China Global License Agreement With Takeda

December 3, 2024

Cooley advised Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its exclusive global development and commercialization license agreement with Takeda Pharmaceuticals to advance elritercept.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Ryan Sansom
Partner, Boston
Marc Recht
Partner, Boston
David Burns
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Bartholomäus Regenhardt
Associate, Brussels
Stella Sarma
Partner, Brussels

Related Practices & Industries

Alentis Therapeutics Closes $181.4 Million Series D

November 12, 2024

Cooley advised Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive tumors and organ fibrosis, on its $181.4 million oversubscribed Series D financing round. Partners Brandon Fenn and Ryan Sansom led the Cooley team advising Alentis Therapeutics.

Related contacts

Brandon W. Fenn
Partner, New York
Ryan Sansom
Partner, Boston
Alex Abelson
Associate, New York
Michael Bruno
Associate, New York
Robert Warshaw
Associate, New York
Xander Lee
Partner, Santa Monica
Kenneth Krisko
Partner, Reston

Related Practices & Industries

Milestone Pharmaceuticals Enters Into Cooperation Agreement With Alta Fundamental Advisers

July 16, 2024

Cooley advised Milestone Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, on its refreshment of its board of directors and cooperation agreement with Alta Fundamental Advisers.

Read more

Related contacts

Bill Roegge
Partner, New York
Ryan Sansom
Partner, Boston
Zachary Sonenshine
Associate, New York
Sarah Curry
Associate, New York
Samuel Paullin
Associate, Chicago

Related Practices & Industries

Tenet Medicines to Be Acquired by Eliem Therapeutics

April 11, 2024

Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics, a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.

Read more

Related contacts

Elizabeth Galvin
Associate, Boston
Miguel J. Vega
Partner, Boston
Eric Blanchard
Partner, Boston
Ryan Sansom
Partner, Boston
Mike Nelson
Partner, Colorado
Kurtis Zinger
Associate, Colorado
Margaux Arntson
Associate
Stephanie Gentile
Partner, New York
Ryan Montgomery
Partner, Boston
Megan Browdie
Partner, Washington, DC
Phil Mitchell
Partner, New York
Geoffrey Spolyar
Partner, Boston
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Trevor Bossi
Associate, Boston
Wyatt Kernell
Associate, Colorado
Nicollette R. Kirby
Associate, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Amanda Pacheco
Associate, Palo Alto
Steven A. Zuckerman
Associate, New York
Stacy Colter
Senior Paralegal, Colorado
Patricia Myers
Paralegal Specialist, Colorado

Related Practices & Industries

View more

Admissions and credentials

Massachusetts